Loss of PTEN expression is associated with poor prognosis in patients with intraductal papillary mucinous neoplasms of the pancreas.

Targeted next-generation sequencing of cancer genes dissects the molecular profiles of intraductal papillary neoplasms of the pancreas. J Pathol (2014) 1.33

Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev (2016) 1.13

Targeting insulin-like growth factor 1 receptor inhibits pancreatic cancer growth and metastasis. PLoS One (2014) 1.04

Constitutively active Akt1 cooperates with KRas(G12D) to accelerate in vivo pancreatic tumor onset and progression. Neoplasia (2015) 0.86

WWP2 is overexpressed in human oral cancer, determining tumor size and poor prognosis in patients: downregulation of WWP2 inhibits the AKT signaling and tumor growth in mice. Oncoscience (2014) 0.83

Pancreatic adenocarcinoma pathology: changing "landscape". J Gastrointest Oncol (2015) 0.82

Emerging role of the KRAS-PDK1 axis in pancreatic cancer. World J Gastroenterol (2014) 0.80

Impact of PI3K/AKT/mTOR pathway activation on the prognosis of patients with head and neck squamous cell carcinomas. Oncotarget (2016) 0.80

[Classification and malignant potential of pancreatic cystic tumors]. Pathologe (2015) 0.79

Growth hormone receptor inhibition decreases the growth and metastasis of pancreatic ductal adenocarcinoma. Exp Mol Med (2014) 0.79

Entamoeba histolytica Cysteine Proteinase 5 Evokes Mucin Exocytosis from Colonic Goblet Cells via αvβ3 Integrin. PLoS Pathog (2016) 0.78

Overexpression of PIK3CA in murine head and neck epithelium drives tumor invasion and metastasis through PDK1 and enhanced TGFβ signaling. Oncogene (2016) 0.78

Loss of Activin Receptor Type 1B Accelerates Development of Intraductal Papillary Mucinous Neoplasms in Mice With Activated KRAS. Gastroenterology (2015) 0.77

Decreased RGS6 expression is associated with poor prognosis in pancreatic cancer patients. Int J Clin Exp Pathol (2014) 0.76

Pancreas-specific activation of mTOR and loss of p53 induce tumors reminiscent of acinar cell carcinoma. Mol Cancer (2015) 0.75

Comparison of the diagnostic accuracy of three current guidelines for the evaluation of asymptomatic pancreatic cystic neoplasms. Medicine (Baltimore) (2017) 0.75

Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science (2008) 36.02

The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer (2002) 28.11

High frequency of mutations of the PIK3CA gene in human cancers. Science (2004) 27.94

A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature (2007) 10.98

International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. Pancreatology (2006) 8.83

Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell (2005) 7.87

Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc Natl Acad Sci U S A (2005) 6.62

PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet (1999) 6.18

The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol (2004) 5.43

Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int J Cancer (1995) 5.24

Intraductal papillary mucinous neoplasms of the pancreas: an updated experience. Ann Surg (2004) 5.12

PDK1, the master regulator of AGC kinase signal transduction. Semin Cell Dev Biol (2004) 5.10

Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development. Sci Transl Med (2011) 5.03

Cancer-specific mutations in PIK3CA are oncogenic in vivo. Proc Natl Acad Sci U S A (2006) 4.84

An illustrated consensus on the classification of pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms. Am J Surg Pathol (2004) 4.74

Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways. Proc Natl Acad Sci U S A (2011) 3.51

Oncogenic mutations of PIK3CA in human cancers. Cell Cycle (2004) 3.47

Pten constrains centroacinar cell expansion and malignant transformation in the pancreas. Cancer Cell (2005) 3.15

Classification of types of intraductal papillary-mucinous neoplasm of the pancreas: a consensus study. Virchows Arch (2005) 2.76

A new mutational AKTivation in the PI3K pathway. Cancer Cell (2007) 2.62

Germline and somatic mutations of the STK11/LKB1 Peutz-Jeghers gene in pancreatic and biliary cancers. Am J Pathol (1999) 2.59

Mucinous cystic neoplasm of the pancreas is not an aggressive entity: lessons from 163 resected patients. Ann Surg (2008) 2.45

Mutation of the PIK3CA gene in anaplastic thyroid cancer. Cancer Res (2005) 2.10

Frequent genetic and biochemical alterations of the PI 3-K/AKT/PTEN pathway in head and neck squamous cell carcinoma. Int J Cancer (2005) 1.95

PIK3CA mutations in head and neck squamous cell carcinoma. Clin Cancer Res (2006) 1.90

STK11/LKB1 Peutz-Jeghers gene inactivation in intraductal papillary-mucinous neoplasms of the pancreas. Am J Pathol (2001) 1.89

AKT1(E17K) in human solid tumours. Oncogene (2008) 1.87

PTEN loss accelerates KrasG12D-induced pancreatic cancer development. Cancer Res (2010) 1.65

PIK3CA mutations in intraductal papillary mucinous neoplasm/carcinoma of the pancreas. Clin Cancer Res (2006) 1.63

Cystic lesions and neoplasms of the pancreas. The features are becoming clearer. Pancreatology (2001) 1.55

Prevalence of activating K-ras mutations in the evolutionary stages of neoplasia in intraductal papillary mucinous tumors of the pancreas. Ann Surg (1997) 1.55

Intraductal papillary-mucinous tumours represent a distinct group of pancreatic neoplasms: an investigation of tumour cell differentiation and K-ras, p53 and c-erbB-2 abnormalities in 26 patients. Virchows Arch (1994) 1.54

BRAF and KRAS gene mutations in intraductal papillary mucinous neoplasm/carcinoma (IPMN/IPMC) of the pancreas. Cancer Lett (2006) 1.46

Intraductal papillary mucinous neoplasm (IPMN) of the pancreas: its histopathologic difference between 2 major types. Am J Surg Pathol (2006) 1.46

SNP Cutter: a comprehensive tool for SNP PCR-RFLP assay design. Nucleic Acids Res (2005) 1.40

Dissecting the role of the 3-phosphoinositide-dependent protein kinase-1 (PDK1) signalling pathways. Cell Cycle (2008) 1.37

Clinical importance of precursor lesions in the pancreas. J Hepatobiliary Pancreat Surg (2007) 1.31

Intraductal papillary mucinous neoplasm. Hum Pathol (2011) 1.26

Methylation of cyclin D2 is observed frequently in pancreatic cancer but is also an age-related phenomenon in gastrointestinal tissues. Clin Cancer Res (2003) 1.22

Pancreatic intraductal papillary-mucinous neoplasms: a new and evolving entity. Virchows Arch (2007) 1.06

Novel mutant-enriched sequencing identified high frequency of PIK3CA mutations in pharyngeal cancer. Int J Cancer (2008) 1.05

K-Ras and microsatellite marker analysis of fine-needle aspirates from intraductal papillary mucinous neoplasms of the pancreas. Diagn Cytopathol (2006) 1.04

Different subtypes of intraductal papillary mucinous neoplasm in the pancreas have distinct pathways to pancreatic cancer progression. J Gastroenterol (2011) 1.02

Somatic mutations in PIK3CA and activation of AKT in intraductal tubulopapillary neoplasms of the pancreas. Am J Surg Pathol (2011) 1.00

Genomic profiling maps loss of heterozygosity and defines the timing and stage dependence of epigenetic and genetic events in Wilms' tumors. Mol Cancer Res (2005) 0.94

Does "clonal progression" relate to the development of intraductal papillary mucinous tumors of the pancreas? J Gastrointest Surg (2004) 0.94

Intraductal papillary mucinous neoplasms of the pancreas. J Clin Gastroenterol (2008) 0.90

High-throughput mutation profiling in intraductal papillary mucinous neoplasm (IPMN). J Gastrointest Surg (2011) 0.90

AKT1 (E17K) mutation in pancreatic cancer. Technol Cancer Res Treat (2008) 0.87

Pancreatic intraepithelial neoplasia-can we detect early pancreatic cancer? Histopathology (2010) 0.85

Functional consequences of mutations in a putative Akt phosphorylation motif of B-raf in human cancers. Mol Carcinog (2005) 0.84

PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res (2005) 8.98

Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. Nat Med (2007) 6.55

Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. Proc Natl Acad Sci U S A (2007) 5.44

The New York Cancer Project: rationale, organization, design, and baseline characteristics. J Urban Health (2004) 5.21

Integrated analysis of homozygous deletions, focal amplifications, and sequence alterations in breast and colorectal cancers. Proc Natl Acad Sci U S A (2008) 4.13

Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair. Nat Genet (2007) 3.95

Gastrointestinal stromal tumors: radiologic features with pathologic correlation. Radiographics (2003) 3.54

Meta-analysis of randomized educational and behavioral interventions in type 2 diabetes. Diabetes Educ (2003) 3.05

Cell type-specific DNA methylation patterns in the human breast. Proc Natl Acad Sci U S A (2008) 2.99

Lack of PTEN sequesters CHK1 and initiates genetic instability. Cancer Cell (2005) 2.98

Cooperativity of Nkx3.1 and Pten loss of function in a mouse model of prostate carcinogenesis. Proc Natl Acad Sci U S A (2002) 2.89

A secreted PTEN phosphatase that enters cells to alter signaling and survival. Science (2013) 2.86

PBAF chromatin-remodeling complex requires a novel specificity subunit, BAF200, to regulate expression of selective interferon-responsive genes. Genes Dev (2005) 2.70

PTEN: from pathology to biology. Trends Cell Biol (2003) 2.69

Distinct IL-2 receptor signaling pattern in CD4+CD25+ regulatory T cells. J Immunol (2004) 2.54

Activation of the PI3K pathway in cancer through inhibition of PTEN by exchange factor P-REX2a. Science (2009) 2.51

SPARC/osteonectin is a frequent target for aberrant methylation in pancreatic adenocarcinoma and a mediator of tumor-stromal interactions. Oncogene (2003) 2.32

Cell cycle checkpoint defects contribute to genomic instability in PTEN deficient cells independent of DNA DSB repair. Cell Cycle (2009) 2.31

BAF180 is a critical regulator of p21 induction and a tumor suppressor mutated in breast cancer. Cancer Res (2008) 2.06

Hypomorphic mutation of PDK1 suppresses tumorigenesis in PTEN(+/-) mice. Curr Biol (2005) 2.00

Pancreatic cancer screening in a prospective cohort of high-risk patients: a comprehensive strategy of imaging and genetics. Clin Cancer Res (2010) 1.92

PIK3CA mutations in head and neck squamous cell carcinoma. Clin Cancer Res (2006) 1.90

The protein phosphatase activity of PTEN regulates SRC family kinases and controls glioma migration. Cancer Res (2008) 1.63

PIK3CA mutations in intraductal papillary mucinous neoplasm/carcinoma of the pancreas. Clin Cancer Res (2006) 1.63

High prevalence of BRCA1 and BRCA2 germline mutations with loss of heterozygosity in a series of resected pancreatic adenocarcinoma and other neoplastic lesions. Clin Cancer Res (2013) 1.63

Incidence and predictors of bowel obstruction in elderly patients with stage IV colon cancer: a population-based cohort study. JAMA Surg (2013) 1.57

Methylation of the PTEN promoter defines low-grade gliomas and secondary glioblastoma. Neuro Oncol (2007) 1.53

Reduced expression of PTEN correlates with breast cancer progression. Hum Pathol (2002) 1.53

BRAF and KRAS gene mutations in intraductal papillary mucinous neoplasm/carcinoma (IPMN/IPMC) of the pancreas. Cancer Lett (2006) 1.46

A prospective cohort study of bladder cancer risk in relation to active cigarette smoking and household exposure to secondhand cigarette smoke. Am J Epidemiol (2007) 1.44

HLTF gene silencing in human colon cancer. Proc Natl Acad Sci U S A (2002) 1.43

Pathological confirmation of nerve-sparing types performed during robot-assisted radical prostatectomy (RARP). BJU Int (2012) 1.43

3-Phosphoinositide-dependent kinase 1 potentiates upstream lesions on the phosphatidylinositol 3-kinase pathway in breast carcinoma. Cancer Res (2009) 1.43

Thyroidectomy using local anesthesia: a report of 1,025 cases over 16 years. J Am Coll Surg (2005) 1.32

Genetic analysis of Pten and Ink4a/Arf interactions in the suppression of tumorigenesis in mice. Proc Natl Acad Sci U S A (2002) 1.30

Clinical trials methods for evaluation of potential reduced exposure products. Cancer Epidemiol Biomarkers Prev (2009) 1.29

Active and passive cigarette smoking and the risk of cervical neoplasia. Obstet Gynecol (2005) 1.29

Laparoscopic distal pancreatectomy offers shorter hospital stays with fewer complications. J Gastrointest Surg (2010) 1.28

Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience. Cancer Chemother Pharmacol (2013) 1.28

LKB1 protein expression in human breast cancer. Appl Immunohistochem Mol Morphol (2006) 1.28

Expression of KIT (CD117) in angiomyolipoma. Am J Surg Pathol (2002) 1.27

PTEN loss inhibits CHK1 to cause double stranded-DNA breaks in cells. Cell Cycle (2005) 1.26

The 3p21 candidate tumor suppressor gene BAF180 is normally expressed in human lung cancer. Oncogene (2005) 1.23

Gab2-mediated signaling promotes melanoma metastasis. Am J Pathol (2009) 1.21

MAP2K4/MKK4 expression in pancreatic cancer: genetic validation of immunohistochemistry and relationship to disease course. Clin Cancer Res (2004) 1.21

Loss of Stk11/Lkb1 expression in pancreatic and biliary neoplasms. Mod Pathol (2003) 1.19

Smoking and risk of fatal prostate cancer in a prospective U.S. study. Urology (2007) 1.18

Thyroidectomy using monitored local or conventional general anesthesia: an analysis of outpatient surgery, outcome and cost in 1,194 consecutive cases. World J Surg (2006) 1.17

High-throughput measurement of the Tp53 response to anticancer drugs and random compounds using a stably integrated Tp53-responsive luciferase reporter. Carcinogenesis (2002) 1.13

HIN-1, an inhibitor of cell growth, invasion, and AKT activation. Cancer Res (2005) 1.13

DNA mismatch repair deficiency accelerates endometrial tumorigenesis in Pten heterozygous mice. Am J Pathol (2002) 1.12

LKB1 protein expression in the evolution of glandular neoplasia of the lung. Clin Cancer Res (2003) 1.11

Requirement of IFI16 for the maximal activation of p53 induced by ionizing radiation. J Biol Chem (2004) 1.11

Better preservation of endocrine function after central versus distal pancreatectomy for mid-gland lesions. Surgery (2010) 1.10

Disruption of p16 and activation of Kras in pancreas increase ductal adenocarcinoma formation and metastasis in vivo. Oncotarget (2011) 1.09

Conditional activin receptor type 1B (Acvr1b) knockout mice reveal hair loss abnormality. J Invest Dermatol (2010) 1.09

Disruption of transforming growth factor beta-Smad signaling pathway in head and neck squamous cell carcinoma as evidenced by mutations of SMAD2 and SMAD4. Cancer Lett (2006) 1.09

Regulation of PTEN inhibition by the pleckstrin homology domain of P-REX2 during insulin signaling and glucose homeostasis. Proc Natl Acad Sci U S A (2013) 1.07

Novel mutant-enriched sequencing identified high frequency of PIK3CA mutations in pharyngeal cancer. Int J Cancer (2008) 1.05

Effects of 5-aza-2'-deoxycytidine on matrix metalloproteinase expression and pancreatic cancer cell invasiveness. J Natl Cancer Inst (2003) 1.05

Molecular analysis of PIK3CA, BRAF, and RAS oncogenes in periampullary and ampullary adenomas and carcinomas. J Gastrointest Surg (2009) 1.04

Anorectal gastrointestinal stromal tumors: CT and MR imaging features with clinical and pathologic correlation. AJR Am J Roentgenol (2003) 1.03

Combining hedgehog signaling inhibition with focal irradiation on reduction of pancreatic cancer metastasis. Mol Cancer Ther (2013) 1.02

Postoperative glycemic control after central pancreatectomy for mid-gland lesions. World J Surg (2007) 1.02

A meta-analysis of the effectiveness of albendazole compared with metronidazole as treatments for infections with Giardia duodenalis. PLoS Negl Trop Dis (2010) 1.01

Phosphatase and tensin homolog regulation of islet growth and glucose homeostasis. J Biol Chem (2005) 1.00

RAGE gene deletion inhibits the development and progression of ductal neoplasia and prolongs survival in a murine model of pancreatic cancer. J Gastrointest Surg (2011) 1.00

Bowel obstruction in elderly ovarian cancer patients: a population-based study. Gynecol Oncol (2012) 0.99

RFP-mediated ubiquitination of PTEN modulates its effect on AKT activation. Cell Res (2013) 0.98

Pancreaticoduodenectomy can be performed safely in patients aged 80 years and older. J Gastrointest Surg (2010) 0.97

Pancreaticogastrostomy: a novel application after central pancreatectomy. J Am Coll Surg (2004) 0.97

Predictive factors of malignancy in pediatric thyroid nodules. Surgery (2011) 0.97

One hundred thirty resections for pancreatic neuroendocrine tumor: evaluating the impact of minimally invasive and parenchyma-sparing techniques. J Gastrointest Surg (2010) 0.96

Readmission after pancreatic resection is not an appropriate measure of quality. Ann Surg Oncol (2012) 0.96

Available carbohydrates, glycemic load, and pancreatic cancer: is there a link? Am J Epidemiol (2010) 0.95

Green and black tea intake in relation to prostate cancer risk among Singapore Chinese. Cancer Causes Control (2012) 0.94

PIK3CA, KRAS, and BRAF mutations in intraductal papillary mucinous neoplasm/carcinoma (IPMN/C) of the pancreas. Langenbecks Arch Surg (2008) 0.94

Combined resection, intraperitoneal chemotherapy, and whole abdominal radiation for the treatment of malignant peritoneal mesothelioma. Am J Clin Oncol (2008) 0.94

Knowledge, attitudes, and behaviors toward skin cancer in Maryland youths. J Adolesc Health (2002) 0.94

Active cigarette smoking, household passive smoke exposure, and the risk of developing pancreatic cancer. Prev Med (2006) 0.93